×
About 17,543 results

ALLMedicine™ Atopic Dermatitis Center

Research & Reviews  5,293 results

Group 2 innate lymphoid cells (ILC2s) are important in typical type 2 immune-mediated d...
https://doi.org/10.1177/03000605211053156
The Journal of International Medical Research; Jin J, Sunusi S et. al.

Jan 21st, 2022 - The prevalence rate of allergic diseases, such as asthma, atopic rhinitis (AR), and atopic dermatitis (AD), has been significantly increasing over the years because of environmental changes. Type 2 immunity is mediated by allergic inflammation ini...

Body dysmorphia in common skin diseases: Results of an observational, cross-sectional m...
https://doi.org/10.1111/bjd.21021
The British Journal of Dermatology; Schut C, Dalgard FJ et. al.

Jan 19th, 2022 - Body dysmorphic disorder (BDD) is a common psychiatric disorder associated with high costs for healthcare systems as patients may repeatedly ask for different, often not effective interventions. BDD symptoms are more prevalent in patients with der...

The Skin and Nose Microbiome and Its Association with Filaggrin Gene Mutations in Pedia...
https://doi.org/10.1159/000520978
Dermatology (Basel, Switzerland); van Mierlo MMF, Pardo LM et. al.

Jan 19th, 2022 - Interactions between the skin barrier, immune system, and microbiome underlie the development of atopic dermatitis (AD). To investigate the skin and nasal microbiome in relation to filaggrin gene (FLG) mutations. A cross-sectional study including ...

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03559270

Jan 19th, 2022 - This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).

see more →

Guidelines  9 results

Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis...
https://www.ncbi.nlm.nih.gov/pubmed/33147660
Dermatology Online Journal; Yim RM, Singh I et. al.

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Considerations on biologicals for patients with allergic disease in times of the COVID-...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300800
Allergy Vultaggio A, Agache I et. al.

Jun 6th, 2020 - The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex pat...

European task force on atopic dermatitis position paper: treatment of parental atopic d...
https://doi.org/10.1111/jdv.15709
Journal of the European Academy of Dermatology and Venere... Vestergaard C, Wollenberg A et. al.

Jun 25th, 2019 - Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the trea...

Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) ...
https://doi.org/10.1111/jdv.14891
Journal of the European Academy of Dermatology and Venere... Wollenberg A, Barbarot S et. al.

Apr 21st, 2018 - This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic revi...

The microbiome in allergic disease: Current understanding and future opportunities-2017...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5899886
The Journal of Allergy and Clinical Immunology; Huang YJ, Marsland BJ et. al.

Mar 5th, 2017 - PRACTALL is a joint initiative of the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergy and Clinical Immunology to provide shared evidence-based recommendations on cutting-edge topics in the field of allergy and ...

see more →

Drugs  451 results see all →

Clinicaltrials.gov  344 results

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03559270

Jan 19th, 2022 - This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD).

A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
https://clinicaltrials.gov/ct2/show/NCT05029895

Jan 19th, 2022 - Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited number of adolescent p...

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT03915496

Jan 13th, 2022 - B7451037 is a randomized, double-blind, placebo-controlled, parallel-group, Phase 2a study to investigate the mechanism of action of PF-04965842 by correlating efficacy outcomes with changes from baseline in key skin and blood biomarkers in adult ...

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis
https://clinicaltrials.gov/ct2/show/NCT04773587

Jan 13th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-II)
https://clinicaltrials.gov/ct2/show/NCT04773600

Jan 13th, 2022 - This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream or vehicle is applied once daily for 4 weeks to subjects with atopic dermatitis.

see more →

News  895 results

Oral Peanut Allergy Tx May Be Even More Effective in Younger Children
https://www.medpagetoday.com/allergyimmunology/allergy/96779

Jan 20th, 2022 - Children under 4 years of age with peanut allergies had significantly higher desensitization and remission rates with oral immunotherapy versus placebo, and younger age appeared to predict better outcomes, the randomized IMPACT study showed. Among...

Survey: Medical Cannabis Use for Skin Conditions Lags Behind Interest, Acceptance
https://www.medscape.com/viewarticle/966921

Jan 20th, 2022 - A majority of adults support the use of medical cannabis for the treatment of skin conditions, but relatively few have actually tried such a product, according to the results of a recent survey. Almost 89% of respondents were in favor of medical c...

Atopic Dermatitis: A supplement to Dermatology News
https://www.mdedge.com/dermatology/article/250775/atopic-dermatitis/atopic-dermatitis-supplement-dermatology-news

Jan 14th, 2022 - PATIENT SATISFACTION WITH TREATMENT REDUCING ITCH BURDEN OF DISEASE IN BLACK PATIENTS BATHING RECOMMENDATIONS Read More.

Hand eczema and atopic dermatitis closely linked
https://www.mdedge.com/dermatology/article/250751/atopic-dermatitis/hand-eczema-and-atopic-dermatitis-closely-linked
Doug Brunk

Jan 14th, 2022 - An estimated 10% of adults report hand eczema each year, but over one’s lifetime, about 15%-20% will experience the condition, which is more common among those with atopic dermatitis (AD), according to Jacob P. Thyssen, MD, PhD.

FDA Approves Two Oral JAK Inhibitors for Moderate-to-Severe Atopic Dermatitis
https://www.medscape.com/viewarticle/966698

Jan 14th, 2022 - The Food and Drug Administration on Jan. 14 approved two oral JAK-1 inhibitors for patients with moderate-to-severe atopic dermatitis (AD) — upadacitinib and abrocitinib — making them the first oral JAK inhibitors available for this indication in ...

see more →

Patient Education  25 results see all →